News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.
Biogen Acquires Felzartamab Rights from TJ Biopharma for Greater China Market
Biogen consolidates global felzartamab rights through strategic acquisition from TJ Biopharma, expanding CD38-directed antibody reach in China market.
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Argo Biopharma doses first patients in Phase II trials of BW-40202, an investigational siRNA therapy targeting complement factor B for PNH and IgAN treatment.
Mabwell Bioscience Passes First PIC/S Member GMP Inspection for Denosumab Biosimilars in Jordan
Mabwell Bioscience achieves milestone regulatory approval as Jordan FDA clears GMP inspection for two denosumab biosimilars, expanding global reach.
Mabwell Subsidiary T-mab Passes Jordan GMP Inspection for Denosumab Biosimilars
Mabwell's T-mab subsidiary receives GMP compliance approval from Jordan FDA for two denosumab biosimilars, marking regulatory milestone for bone treatments.
Quality Executive Partners Partners with Vi'eNnI to Expand Virtuosi Training Platform in India's Pharmaceutical Market
QxP announces exclusive partnership with Vi'eNnI to scale Virtuosi workforce development platform across India's growing pharmaceutical sector.
SynSmart and Amporin Partner to Develop Small Molecule Therapeutics for Degenerative Diseases
SynSmart Rasayan Research and Amporin Pharmaceuticals announce collaboration to develop breakthrough small molecule treatments for fatal degenerative diseases.
Australia's TGA Updates Over-the-Counter Medicine Registration Guidelines for Pharmaceutical Companies
Australia's Therapeutic Goods Administration releases updated guidance on over-the-counter medicine registration requirements for pharmaceutical manufacturers.
Methylphenidate Shortage Update: Concerta and Ritalin LA Supply Restored, Rubifen LA Expected by June 2026
Australia's methylphenidate shortage shows improvement as Concerta and Ritalin LA supplies normalize, while Rubifen LA shortages persist until mid-2026.
PMDA Approves Peripheral Rotablator PRO and Visual-ICE Cryoablation System Modifications in Japan
Japan's PMDA grants partial change approval for Peripheral Rotablator PRO and Visual-ICE Cryoablation System, expanding cardiovascular treatment options.
Alamar Biosciences NASDAQ IPO: Precision Proteomics Company Debuts at $1.5B Valuation
Alamar Biosciences (NASDAQ:ALMR) successfully listed on NASDAQ at $17 per share, opening at $22.6 with $1.5B market cap in precision proteomics breakthrough.
ACT Genomics Expands Cancer Genomic Testing Panel to 101 Genes with 7-Day Turnaround Time
ACT Genomics upgrades ACTDrug genomic testing to 101-gene panel with 7-day results for advanced cancer patients, enhancing precision medicine capabilities.
Qdenga Dengue Vaccine Approved in Australia for Ages 4+ Against All Four Virus Serotypes
Australia's TGA approves Qdenga tetravalent dengue vaccine for protection against all four dengue virus serotypes in patients aged 4 years and older.
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Diseases
Zai Lab's ZL-1503, an IL-13/IL-31Rα bispecific antibody, demonstrates rapid itch relief and inflammation reduction in preclinical atopic disease studies.
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Data
Zai Lab presents promising preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody targeting rapid itch relief and inflammation reduction in atopic diseases.
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Corporation unveiled three innovative cancer treatment programs at AACR 2026, featuring next-generation ADC and TCE technologies for oncology patients.
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Antengene showcases three novel oncology programs at AACR 2026, featuring next-generation ADC technology and AnTenGager T-cell engagers for cancer treatment.
Australia's TGA Expands Therapeutic Vaping Access Through Pharmacy Channels with New Regulatory Framework
Australia's TGA establishes new pathways for therapeutic vaping products through pharmacies, expanding access to regulated e-cigarettes as therapeutic goods.
TGA Updates Medical Device Regulations for AI and Software-Based Therapeutic Products in Australia
Australia's TGA provides comprehensive regulatory guidance for medical devices including AI and software products through ARTG registration and manufacturing standards.
Atara Biotherapeutics Class Action Lawsuit Filed: ATRA Stockholders May Recover Investment Losses from May 2024-January 2026
Robbins LLP announces class action lawsuit for Atara Biotherapeutics (ATRA) investors who purchased securities between May 20, 2024 and January 9, 2026.